当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons
Cancer Discovery ( IF 29.7 ) Pub Date : 2022-07-20 , DOI: 10.1158/2159-8290.cd-22-0703
Paolo Tarantino 1, 2, 3, 4 , Giuseppe Curigliano 3, 4 , Sara M Tolaney 1, 2
Affiliation  

Summary: The confirmation of the HER2-low paradigm is expected to have a major impact in breast oncology. About half of all breast cancers harbor HER2-low expression, which can be targeted with the anti-HER2 antibody–drug conjugate trastuzumab deruxtecan (T-DXd), leading to a relevant survival benefit in the metastatic setting. Given this observation, treatment algorithms for both hormone receptor–positive and triple-negative breast cancer are expected to significantly evolve in the next future. Several challenges, however, remain in the interpretation of HER2-low expression related to its biological role, its pathologic diagnosis, and the definition itself of HER2-low. In this article, we recapitulate the current knowledge on HER2-low breast cancer, discussing whether it should be considered a distinct subtype, how it should be implemented in the clinic, and how its definition may evolve in the coming years with the evolution of our clinical and translational knowledge.

中文翻译:

探索乳腺肿瘤学中 HER2-Low 范式:新标准,未来视野

摘要:HER2-low 范式的确认预计将对乳腺肿瘤学产生重大影响。大约一半的乳腺癌存在 HER2 低表达,可以使用抗 HER2 抗体药物偶联物曲妥珠单抗 deruxtecan (T-DXd) 进行靶向治疗,从而在转移性环境中带来相关的生存获益。鉴于这一观察结果,激素受体阳性和三阴性乳腺癌的治疗算法预计将在未来显着发展。然而,对 HER2-low 表达的解释仍存在一些挑战,包括其生物学作用、病理诊断以及 HER2-low 的定义本身。在本文中,我们概述了当前关于 HER2 低乳腺癌的知识,讨论是否应将其视为一种独特的亚型,
更新日期:2022-07-20
down
wechat
bug